CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) had its target price reduced by equities researchers at Oppenheimer to $10.00 in a note issued to investors on Thursday, Stock Target Advisor reports. Oppenheimer’s price objective points to a potential upside of 197.62% from the company’s previous close. Oppenheimer also issued estimates for CymaBay Therapeutics’ Q4 2022 earnings at ($0.33) EPS, FY2022 earnings at ($1.50) EPS, FY2023 earnings at ($1.28) EPS, FY2024 earnings at ($0.68) EPS, FY2025 earnings at $0.04 EPS and FY2026 earnings at $0.61 EPS.
Separately, StockNews.com assumed coverage on shares of CymaBay Therapeutics in a research report on Wednesday, October 12th. They set a “hold” rating on the stock. One investment analyst has rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.33.
CymaBay Therapeutics Price Performance
Shares of CymaBay Therapeutics stock opened at $3.36 on Thursday. The firm has a fifty day simple moving average of $3.49 and a 200-day simple moving average of $3.10. The company has a current ratio of 12.20, a quick ratio of 13.27 and a debt-to-equity ratio of 1.43. CymaBay Therapeutics has a 1-year low of $1.67 and a 1-year high of $4.30. The stock has a market capitalization of $284.52 million, a price-to-earnings ratio of -2.69 and a beta of 0.54.
Hedge Funds Weigh In On CymaBay Therapeutics
About CymaBay Therapeutics
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis.
- Get a free copy of the StockNews.com research report on CymaBay Therapeutics (CBAY)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.